

TRIAZAVIRIN



A broad-spectrum anti-viral drug for Influenza A & B and Covid-19.

Contact: Charles Fridlender
Charles@pharmachal.com
Drug & Poisons Lic.
No . 24211888
www.pharmachal.com

Over 3 million people have been treated.

Available in Australia on TGA Special Access Scheme (Category A).



REAL WORLD RESULTS

RECOVERY TIME FOR COVID PATIENTS FROM INITIATION OF THERAPY WAS 4.2 DAYS. 94% RECOVERY.

CLINICAL TRIALS HAVE SHOWN BODY TEMP REMAINED <37. REDUCED CARDIAC DAMAGE.

**DOSAGE: 250 MG CAPSULE, 3 / DAY
START BY TAKING 2, THEN 1 THEREAFTER.**

ABOUT TRIAZAVIRIN

Triazavirin (TZV), a non-toxic, broad--spectrum antiviral compound, is efficient against various strains of the Influenza A virus (Influenza Virus A, Orthomyxoviridae), i.e., swine flu (H1N1, or H3N2), avian influenza (H5N1, H5N2, H9N2, or highly pathogenic H7N3 strain), Influenza B virus (Influenza Virus B, Orthomyxoviridae), Respiratory Syncytial Virus (Orthopneumovirus, Pneumoviridae), Tick-Borne Encephalitis Virus (known as Forest-Spring Encephalitis Virus; Flavivirus, Flaviviridae), West Nile Virus (Flavivirus, Flavaviridae), Rift Valley Fever Virus (Phlebovirus, Bunyaviridae), and Herpes viruses (Simplexviruses, Herpesviridae) as well.